MedTrace Logo

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

NCT00960804 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-02-08

Study results available
· View outcomes & findings →

Summary

Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves

Conditions

Interventions

BIOLOGICAL

Tanezumab

IV, 5 mg dose, q 8 weeks, for up to 80 weeks

BIOLOGICAL

Tanezumab

IV, 10 mg dose, q 8 weeks, for up to 80 weeks

OTHER

Placebo

IV, q 8 weeks, for up to 80 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-15
Primary Completion
2010-11-11
Completion
2010-11-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00960804 on ClinicalTrials.gov